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Urogenitalinfectionsofbacterialoriginhaveahighincidenceamongtheworldfemalepopulationatreproductiveage.Lactobacilli,
the predominant microorganisms of the healthy vaginal microbiota, have shown a protective eﬀect against the colonization and
overgrowth of urogenital pathogens that increased the interest for including them into probiotics products assigned to restore the
urogenital balance. In the present work, we determined in a mouse animal model the capability of Lactobacillus paracasei CRL
1289, a human vaginal strain with probiotic properties, to prevent the vaginal colonization of a uropathogenic strain of Staphylo-
coccus aureus. Six-week-old female BALB/c mice, synchronized in their estral cycle, were intravaginally inoculated with two doses
of 109 lactobacilli before challenging them with a single dose of 105 or 107 CFU of S. aureus. The vaginal colonization of both
microorganisms and the eﬀect on the vaginal structure were determined at 2, 5, and 7 days after pathogen inoculation. Control
mice and those challenged only with the pathogen showed an insigniﬁcant lactobacilli population, whereas 105 lactobacilli/mL of
vaginal homogenate were recovered at 2 days after challenge from the L. paracasei CRL 1289 and the probiotic + pathogen groups,
decreasing this number on the following days. The treatment with L. paracasei CRL 1289 decreased signiﬁcantly the number of
staphylococci recovered at 2 and 5 days when mice were challenged only with 105 CFU of pathogen. The inoculation of S. aureus
produced a remarkable inﬂammatory response and structural alterations in the vaginal mucosa that decreases in a signiﬁcant
manner when the mice were protected with L. paracasei CRL 1289. The results obtained suggest that this particular Lactobacillus
strain could prevent the onset of urogenital infections by interfering with the epithelial colonization by uropathogenic S. aureus.
Copyright © 2007 Gabriela Z´ arate et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Urogenital tract infections of bacterial origin have a high in-
cidence among the world female population at reproductive
age. A great proportion of these diseases, such as vaginosis
and urinary tract infections are often caused by pathogens
that emerge from the intestinal microbiota and ascend along
perineum to the vagina and then to the urethra and bladder
[1].Whileantibioticshavebeenextensivelyusedasaquiteef-
fective therapy for the treatment of these bacterial infections,
the increasing drug resistance of urogenital pathogens makes
imperative the development of alternative therapeutics.
In healthy women, the vaginal microﬂora is dominated
by Lactobacillusspecies,atalevelof107-108 CFU g−1 ofﬂuid,
which exert a signiﬁcant inﬂuence on the microbiology of
the ecosystem [2]. It has been observed that indigenous lac-
tobacilli prevent the overgrowth and invasion of pathogenic
bacteria[3]byacombinationofcompetitive exclusion, com-
petitionfornutrients,andreleaseofantimicrobialsubstances
such as hydrogen peroxide, organic acids, bacteriocins, and
biosurfactants [3–6]. In consequence, a depletion of vagi-
nal lactobacilli has been directly associated with an increase
in the incidence of genital and urinary infections [7–9]. For
this reason, there is a growing interest in the use of human
lactobacilli as probiotics that restore and maintain a nor-
mal vaginal ﬂora and prevent disease recurrence by form-
ing a pellicle on the vaginal epithelium as a biological bar-
rieragainstcolonizationofpathogenicbacteria.Inthissense,
previous studies have reported that adhesive lactobacilli can
inhibit in vitro the attachment of pathogens such as Es-
cherichia coli, Gardnerella vaginalis, Candida albicans, Pseu-
domonas aeruginosa, Klebsiella pneumoniae, Staphylococcus
aureus,a n dStreptococcus agalactiae to urogenital epithelial
cells [5, 10–13].2 Infectious Diseases in Obstetrics and Gynecology
Having in mind the objective of developing a probiotic
formulation for the prevention and therapy of urogenital
tract infections, our research group has previously isolated
andidentiﬁedvaginallactobacillifromhealthywomenofTu-
cum´ an city in Argentina [14]. The strains were extensively
characterized for their probiotic and technological features
and some promising properties such as adhesion, auto and
coaggregation abilities, hydrogen peroxide, bacteriocin-like
substances, and organic acids production were reported [15–
18]. Relevant technological properties, for instance, the op-
timal conditions for the production of antimicrobial sub-
stances and the viability and biological properties after pro-
cessing, were also determined for selected strains [19–24].
Lactobacillus paracasei CRL 1289 is a selected human
vaginal strain selected by its probiotic potential, since it is
able to inhibit the growth of uropathogenic Staphylococcus
aureus in vitro by release of H2O2 [20], and its adhesion to
vaginal epithelial cells by exclusion and competence for spe-
ciﬁc receptors [24]. Staphylococcus aureus is a major oppor-
tunistic pathogen that can cause a variety of local and sys-
temic infections ranging from skin abscesses, bone and soft
tissue surgical infections, sepsis, invasive endocarditis, and
toxic shock syndrome (TSS) [25]. TSS is a geographically
widespread disease aﬀecting mainly young healthy menstru-
ating women, especially those using tampons [26].
Theaimofthepresentworkwastodetermine,inamouse
animal model, the capability of Lactobacillus paracasei CRL
1289 to prevent the vaginal colonization of uropathogenic
Staphylococcus aureus.
2. MATERIALS AND METHODS
2.1. Microorganismsandgrowthconditions
LactobacillusparacaseiCRL1289wasoriginallyisolatedfrom
vaginal smears of healthy women [14] and was previously
characterized by their probiotic and technological properties
[15, 20, 22–24]. The human uropathogenic strain of Staphy-
lococcus aureus used in this study was kindly provided by
the Institute of Microbiology “LuisVerna” of the University
of Tucum´ an, Argentina, and was isolated from pathological
urine. Before experimental use, each strain stored in milk-
yeastextractat −20◦CwaspropagatedinLAPTgbroth(1.5%
peptone, 1% tryptone, 1% glucose, 1% yeast extract, and
0.1%Tween80,pH6.8)[27]at37 ◦Candsubcultur edatleast
twice in this media every 12 hours. Lactobacilli were culti-
vated under static conditions in order to avoid the detrimen-
tal eﬀects of oxygen whereas staphylococci were incubated
with shaking at 100rpm.
2.2. Animals
Six-week-old female BALB/c mice from the inbreed colony
of CERELA (Centro de Referencia para Lacobacilos), each
weighing from 25 to 30g, were used throughout the inves-
tigation. Animals were housed in plastic cages and fed ad li-
bitum with a conventional balanced diet, keeping their en-
vironmental conditions constant. All the animals were syn-
chronized in their estrous cycle with an intramuscular single
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Figure 1: Scheme of inoculation of L. paracasei CRL 1289 and
Staphylococcus aureus on Balb/c mice. H: hormone (estradiol valer-
a t e ) ,L :l a c t o b a c i l l ii n o c u l a t i o n ,P :p a t h o g e ni n o c u l a t i o n ,L+P :l a c -
tobacilli plus pathogen inoculation, S: sacriﬁce of animals, and Gg:
glycogelatin ovules without microorganisms.
dose of 0.5mg of estradiol valerate (Progynon Depot. Scher-
ingLaboratories)andrandomlyassignedtothefollowingex-
perimental groups: (1) lactobacilli treated group, (2) lacto-
bacilli + pathogen treated group, and (3) pathogen treated
group. Five animals were used as control synchronized non-
treated group. The CERELA Committee of Ethics approved
the protocol used for animal studies.
2.3. Microorganismsinoculationprocedure
A spontaneous rifampicin resistant strain obtained by plat-
ing L. paracasei CRL 1289 on Rogosa agar (Merck) supple-
mented with 150µg/mL of rifampicin was used to inoculate
mice. The resistant strain showed exactly the same proper-
ties of the original strain. Overnight cultures of lactobacilli
and staphylococci grown on Laptg broth (12 hours, 37◦C)
were centrifuged (10000g, 10 minutes, 4◦C), washed twice
with sterile saline solution, and incorporated into glycoge-
latin ovules at a concentration of 109 CFU of lactobacilli and
105 and 107 CFU of S. aureus per each ovule. The base prepa-
ration of the ovules was obtained by mixing 21% gelatin and
58% glycerol in distilled water. This matrix was sterilized at
121◦Cf o r1 5m i n u t e s ,a n ds u p p l e m e n t e dwi t h0 . 5 %a s c o r b i c
acid and the suspensions of microorganisms in a proportion
1 : 5. Forty-eight hours after estradiol synchronization, an-
imals of groups 1 and 2 were intravaginally inoculated with
twodosesof109 lactobacilli(witha24-hourintervalbetween
each other). On the third day, the animals of group 2 and
thosebelongingtogroup3werechallengedwithasingledose
of 105 or 107 CFU ofuropathogenic S.aureus.Figure 1shows
the inoculation protocol used.
2.4. Bacterialcountsinvaginalhomogenates
At 2, 5, and 7 days after pathogen inoculation, the animals
weresacriﬁcedbycervicaldislocation.Thevaginaofeachan-
imal was removed aseptically, placed in 0.5% peptone-water,
and homogenized with a Teﬂon pestle. Serial ten-fold di-
lutions from this homogenate were plated on Rogosa agar
(LBS, Merck); Rogosa agar supplemented with 150µg/mL of
rifampicin and Manitol Salt Agar (MSA, Britania) for counts
of lactic acid bacteria, L. paracasei CRL 1289, and S. aureus,
respectively. The LBS plates were incubated 72 hours under
microaerophilic conditions whereas MSA plates were aerobi-
cally incubated.Gabriela Z´ arate et al. 3
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Figure 2: Viable counts of lactobacilli (panel A) and staphylococci (panel B) on the vagina of mice inoculated only with these microorgan-
isms or pretreated with L. paracasei CRL 1289 and challenged with uropathogenic S. aureus.P a n e lA :( ) L. paracasei CRL 1289 inoculated,
( ) lactobacilli counted at 2 days after inoculation; ( ) lactobacilli counted at 5 days; ( ) lactobacilli counted at 7 days. Panel B: ( ) S.
aureus inoculated; ( ) staphylococci counted at 2 days; ( ) staphylococci counted at 5 days; ( ) staphylococci counted at 7 days after
inoculation.
2.5. Cytologicalandhistologicalstudies
The cytological and histological evaluations were carried out
by light microscopy. For cytological studies, 50µL of vaginal
exudates were collected with a micropipette tip, spread onto
glass slides, and stained with Giemsa. For the study of histo-
logicalstructures,thevaginaswereasepticallyremoved,ﬁxed
with 10% paraformaldehyde for 24 hours at room tempera-
t u r e ,a n dt h e ne m b e d d e di np a r a ﬃn according to standard
histological methods [28]. Serial paraﬃns e c t i o n so f4 µm
were stained with hematoxylin-eosin and observed at 40X.
2.6. Statisticalanalysis
The results are expressed as the mean value ± standard devi-
ation of the data obtained from three animals at each sample
time of two independent experiments. Signiﬁcant diﬀerences
betweenmeansweredeterminedbyTukey’stestafteranalysis
ofvariance(ANOVA)withMinitabStatisticProgram,release
12forWindows.AP valueof<.05wasconsideredstatistically
signiﬁcant.
3. RESULTS
Figure 2(a) shows the viable counts of lactobacilli and
Figure 2(b) those of staphylococci on the vaginal ho-
mogenates of Balb/c mice at diﬀerent sampling times af-
ter inoculation of probiotic L. paracasei CRL 1289 and
uropathogenic S. aureus. Synchronized nontreated mice and
those challenged only with the pathogen (Group 3) showed
an insigniﬁcant lactobacilli population. On the other side,
105 lactobacilli/mL of vaginal homogenate were recovered
from the group inoculated only with probiotic L. paracasei
CRL 1289 (Group 1) and the probiotic + pathogen group
(Group2)at2daysafterchallenge.However,thisnumberde-
creased progressively on the following days (see Figure 2(a)).
Referred to the number of pathogens recovered from
mice, control group and the lactobacilli treated group
(Group 1) were almost depleted of staphylococci population
(Figure 2(b)). The inoculation of 107 CFU of S. aureus pro-
duced a high and constant colonization of the pathogen that
was not prevented by the pretreatment with lactobacilli (re-
sults not shown). However, the treatment with L. paracasei
CRL 1289 previous to the pathogen infection decreased sig-
niﬁcantly the number of staphylococci recovered at 2 and
5 days when mice were challenged with 105 CFU of the
pathogen (Figure 2(b)).
Figure 3 shows the vaginal smears stained with Giemsa
of mice inoculated with lactobacilli and staphylococci. No
cytological modiﬁcations were observed after the adminis-
tration of L. paracasei CRL 1289. By the contrary, the inocu-
lation of S. aureus produced a remarkable inﬂammatory re-
sponse (Group 3) with a high inﬁltration of polymorphonu-
clear cells in the vaginal secretions. This eﬀect decreased in
a signiﬁcant manner when mice were previously protected
with L. paracasei CRL 1289.
No histological alterations were produced by the lacto-
bacilli inoculation (Figure 4), whereas signiﬁcant structural
modiﬁcations of the vaginal mucosa, with disappearance of
the keratin layer and neutrophiles inﬁltration in the epithe-
lium, were observed in the group inoculated solely with S.
aureus (Figure 4). An intermediate eﬀect was observed in
mice protected with L. paracasei CRL 1289.
4. DISCUSSION
Thepotentialuseofhumanlactobacilliasprobioticsassigned
torestoreandmaintainahealthyurogenitaltractrepresentsa4 Infectious Diseases in Obstetrics and Gynecology
(a) (b)
(c) (d)
Figure 3: Vaginal smears stained with Giemsa of mice that were inoculated with lactobacilli and/or staphylococci. (a) Lactobacilli treated
group; (b), (c) lactobacilli + pathogen treated group; (d) pathogen treated group. Magniﬁcation is 40X.
(a) (b) (c)
(d) (e) (f)
Figure 4: Light microscopy photographs of histological slices stained with hematoxylin-eosin showing the mucosa structure of the vaginas
of mice that were inoculated with lactobacilli and/or staphylococci. (a), (b) Lactobacilli treated groups at 10X and 100X, respectively. (c), (d)
Lactobacilli + pathogen treated groups at 40X and 100X. (e), (f) Pathogen treated groups at 40X and 100X magniﬁcations, respectively. For
d e t a i l ss e eM a t e r i a l sa n dM e t h o d s .
promising alternative to conventional chemotherapy [6, 29].
At present, a lot of scientiﬁc evidence supports, by in vitro
and in vivo studies, the eﬀectiveness of probiotics to prevent
the attachment or stimulate the removal of enteropathogens
from intestinal cells [30, 31]. Probiotics have been suc-
cessfully used to prevent and treat gastrointestinal diseases
caused by antibiotics treatments, rotavirus, enterobacteria
andclostridiainfections[32].However,therearemuchlesser
antecedents on the preventive and therapeutic eﬀects of pro-
biotics against diseases of the urogenital tract. Some in vitro
studies have reported the inhibition of pathogens growth
and adherence to uroepithelial cells by lactobacilli [10, 12,
13, 21, 24, 33]. This “anti-infective” mechanism involves the
release of antimicrobials and the blockage of uropathogensGabriela Z´ arate et al. 5
adherence by both steric hindrance and competition for re-
ceptors [10, 34]. With respect to in vivo studies, it has been
reported that vaginal lactobacilli prevented urinary tract col-
onization of mice by E. coli but were not able to exert sig-
niﬁcant therapeutic eﬀects [35]. In humans, clinical eﬃcacy
for urogenital health maintenance and disease prevention
has been demonstrated only for Lactobacillus rhamnosus GR-
1a n dLactobacillus reuteri RC-14 [1]. Both probiotic lacto-
bacilli strains colonized the urogenital tract by vaginal instil-
lationandoralconsumption,andwereabletoreducetherisk
of UTI and cure bacterial vaginosis [36, 37].
In the healthy urogenital tract of adult females, it is
supposed that the indigenous lactobacilli exclude the colo-
nization of pathogenic bacteria by antagonistic compounds
and/or by occupying/masking their potential binding sites in
the mucosa [10, 38]. However, in a depleted lactobacilli en-
vironment such as an infected urogenital tract, it should be
expected that exogenous probiotic lactobacilli have the ca-
pacity to compete for the same receptors and displace pre-
viously attached pathogens [11] .I nap r e v i o u ss t u d y ,w eo b -
served that selected vaginal lactobacilli interfered to diﬀer-
ent extents with the growth and adherence to vaginal epithe-
lial cells of some genitourinary pathogens [21, 24]. Among
these strains, Lactobacillus paracasei CRL 1289 was able to
decrease, in a signiﬁcant level, the adhesion of S. aureus
by exclusion and competition mechanisms [24], as well as
to inhibit its growth by H2O2 production [15, 20]. Based
on these ﬁndings, we evaluated in the present work the
ability of these lactobacilli to prevent the vaginal coloniza-
tion of S. aureus in an animal model, and the protection
achieved.
The results obtained showed that lactobacilli were not
a dominant population of the vaginal microbiota of the
Balb/c mice used in this study and that human Lactobacil-
lus paracasei CRL 1289 was able to colonize transiently
the murine vaginal tract, since 105 lactobacilli/mL of vagi-
nal homogenate were recovered after 2 days of inoculation
but decreased progressively on the following days. How-
ever, the human S. aureus uropathogenic strain was able to
produce a very strong infection when inoculated at 105 or
107 CFU levels, producing signiﬁcant morphological alter-
ations of the mucosal structure, mainly the inﬁltration of
polymorphonuclear cells that appeared as capsulated groups
of cells in the vaginal epithelium and lamina propia; and
the complete disappearance of the keratin layer. Lactobacil-
lus paracasei CRL 1289 was not able to protect mice chal-
lenged with 107 CFU of S. aureus but eﬀectively decreased
the number of staphylococci in the vagina and the dam-
age caused, when the infecting dose of the pathogen was
105 CFU.
In conclusion, the preliminary results obtained in this
work suggest that L. paracasei CRL 1289 could prevent the
onset of urogenital infections caused by uropathogenic S.
aureus interfering with the epithelial colonization (possi-
bly through barrier/interference mechanisms) and encour-
age further in vivo studies, such as clinical trials designed to
test their capacity to prevent and manage urogenital tract in-
fections in females.
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